News stories about Fluidigm (NASDAQ:FLDM) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fluidigm earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 44.8866248079024 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
Shares of Fluidigm (NASDAQ FLDM) traded down $0.37 during mid-day trading on Wednesday, reaching $7.19. The company had a trading volume of 293,632 shares, compared to its average volume of 217,056. The company has a market capitalization of $264.35, a PE ratio of -3.78 and a beta of 3.24. Fluidigm has a 52-week low of $2.52 and a 52-week high of $7.75. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02.
Fluidigm (NASDAQ:FLDM) last issued its earnings results on Thursday, February 8th. The medical research company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $27.75 million during the quarter, compared to the consensus estimate of $27.14 million. Fluidigm had a negative return on equity of 116.02% and a negative net margin of 59.38%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business earned ($0.32) earnings per share. research analysts anticipate that Fluidigm will post -0.7 EPS for the current fiscal year.
Several brokerages have recently issued reports on FLDM. ValuEngine downgraded shares of Fluidigm from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 9th. BidaskClub raised Fluidigm from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $6.10 target price on shares of Fluidigm in a research report on Thursday, February 8th.
In related news, insider Levin Capital Strategies, L.P. acquired 20,380 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was bought at an average cost of $5.71 per share, with a total value of $116,369.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have acquired 482,624 shares of company stock valued at $2,917,895. Company insiders own 4.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-fluidigm-fldm-stock-price.html.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.